Morphic Holding

Morphic Holding PEG

Delisted

PEG Ratio (Price/Earnings-to-Growth) of Morphic Holding (MORF) as of Oct 21, 2026.

PEG

-

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of Morphic Holding is 2026 - . PEG Ratio (Price/Earnings-to-Growth) of Morphic Holding was 2025 -1.20 . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Morphic Holding Stock analysis

What does Morphic Holding do? Morphic Holding Inc. is a pharmaceutical company that focuses on developing therapies for serious diseases. The company was founded in 2015 and is based in Waltham, Massachusetts. The company's business model is centered around developing drugs based on "Morphic Molecules" that are specifically designed to interact with certain target proteins in the body. These molecules aim to improve the treatment of diseases such as autoimmune diseases and fibrosis. Morphic Holding Inc. collaborates closely with leading scientists in the field of structural biology to develop new therapy options for patients. The company has formed partnerships with Biogen, Janssen Biotech, and AbbVie to collaboratively develop new medications. In addition to partnering with other leading companies in the healthcare industry, Morphic Holding Inc. also maintains its own research department focused on the discovery and development of new compounds. The company has applied for and been granted several patents for its "Morphic Molecules," further strengthening its ability to develop innovative therapies for serious diseases. One of Morphic Holding Inc.'s current products is a drug for the treatment of cystic fibrosis that is still in the development phase. The company is working to advance its research and development in this area to continue offering innovative therapies for patients. Morphic Holding Inc. is also involved in biotechnological development and offers services to assist other companies in developing new compounds. These services include the identification and validation of target proteins, the design and synthesis of molecules, and the optimization of drug properties. In conclusion, Morphic Holding Inc. is an emerging force in the pharmaceutical development field. The company has a unique approach to drug development and has already established partnerships with other companies and leading research institutions to develop new therapy options for patients. With its commitment to innovation and research, Morphic Holding Inc. is likely to continue making significant advancements in the field of medicine in the future. Morphic Holding is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Morphic Holding stock

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) Morphic Holding since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s Morphic Holding with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Morphic Holding

All Key Metrics — Morphic Holding